BioCurex, Inc.(fka BOCX)

[opportunityknocking]

Half in your post it said,
"the technology lends itself to diseases that require blood-based tests (such as multiple sclerosis, Alzheimer's or other central nervous system diseases), compared to prostate or breast cancers in which a biopsy is required."

IMO that is exactly why the recaf technology is going to be a blockbuster. It is noninvasive. We eliminate unnecessary biopsies, it's quick, and it's inexpensive.